Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX) have received an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $32.50.

A number of equities analysts have weighed in on BDSX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Biodesix to a “sell” rating in a report on Saturday, September 13th. Finally, Canaccord Genuity Group set a $20.00 target price on shares of Biodesix and gave the stock a “buy” rating in a report on Friday, September 19th.

Insider Activity

In other news, Director Jack W. Schuler purchased 174,418 shares of the company’s stock in a transaction dated Friday, August 29th. The shares were purchased at an average cost of $8.60 per share, for a total transaction of $1,499,994.80. Following the purchase, the director directly owned 1,220,327 shares in the company, valued at approximately $10,494,812.20. This represents a 16.68% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders acquired 334,836 shares of company stock valued at $2,611,362 and sold 293 shares valued at $2,461. 30.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Blair William & Co. IL increased its position in shares of Biodesix by 33.3% during the 1st quarter. Blair William & Co. IL now owns 124,100 shares of the company’s stock valued at $78,000 after purchasing an additional 31,000 shares during the last quarter. XTX Topco Ltd bought a new stake in Biodesix during the first quarter valued at approximately $64,000. Birchview Capital LP increased its holdings in Biodesix by 2.8% during the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company’s stock valued at $3,586,000 after buying an additional 154,937 shares during the last quarter. Finally, Monashee Investment Management LLC increased its holdings in Biodesix by 15.7% during the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company’s stock valued at $2,532,000 after buying an additional 549,121 shares during the last quarter. 20.96% of the stock is owned by hedge funds and other institutional investors.

Biodesix Price Performance

Shares of NASDAQ BDSX opened at $7.79 on Friday. The firm has a market cap of $62.01 million, a P/E ratio of -1.40 and a beta of 0.98. Biodesix has a twelve month low of $3.44 and a twelve month high of $32.20. The company has a quick ratio of 2.14, a current ratio of 1.84 and a debt-to-equity ratio of 41.11. The company has a 50 day moving average of $7.55 and a 200 day moving average of $7.38.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million during the quarter, compared to analyst estimates of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. Biodesix has set its FY 2025 guidance at EPS. As a group, research analysts expect that Biodesix will post -0.35 EPS for the current fiscal year.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.